|
gptkbp:instanceOf
|
gptkb:malaria_vaccine
|
|
gptkbp:administeredAtAges
|
18 months
5 months
6 months
7 months
|
|
gptkbp:administeredBy
|
gptkb:Africa
injection
Asia (limited trials)
|
|
gptkbp:alsoKnownAs
|
gptkb:Mosquirix
|
|
gptkbp:approvedBy
|
gptkb:Ghana
gptkb:Kenya
gptkb:Malawi
gptkb:World_Health_Organization
2021
|
|
gptkbp:clinicalTrialsBegan
|
2009
|
|
gptkbp:collaboratedWith
|
gptkb:PATH_Malaria_Vaccine_Initiative
|
|
gptkbp:contains
|
gptkb:protein
adjuvant AS01
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:dosesRequired
|
four
|
|
gptkbp:effect
|
about 30-50% against severe malaria
|
|
gptkbp:firstMalariaVaccineApproved
|
true
|
|
gptkbp:fundedBy
|
gptkb:GAVI
gptkb:UNICEF
gptkb:Global_Fund
gptkb:Bill_&_Melinda_Gates_Foundation
|
|
gptkbp:includedIn
|
WHO pilot program
|
|
gptkbp:indication
|
children
|
|
gptkbp:notRecommendedFor
|
adults
pregnant women
|
|
gptkbp:pilotProgramLaunchedIn
|
2019
|
|
gptkbp:reduces
|
severe malaria
malaria cases
malaria-related deaths
malaria-related hospitalizations
|
|
gptkbp:sideEffect
|
fever
injection site pain
irritability
convulsions (rare)
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:target
|
gptkb:Plasmodium_falciparum
|
|
gptkbp:targetsAntigen
|
circumsporozoite protein
|
|
gptkbp:type
|
subunit vaccine
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:WHORecommendedFor
|
children in sub-Saharan Africa
|
|
gptkbp:bfsParent
|
gptkb:Plasmodium_falciparum
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
RTS,S
|